Advancements in Therapy for Acute Lymphoblastic Leukemia: Blinatumomab
نویسندگان
چکیده
© 2016 Harborside Press® Acute lymphoblastic leukemia (ALL) is a rare form of leukemia, with an estimated 6,250 new cases diagnosed in the United States in 2015 and approximately 1,450 deaths (American Cancer Society, 2015). With current available induction therapies, complete remission (CR) rates in adults are approximately 75% to 90% (Faderl et al., 2010; Bassan & Hoelzer, 2011). After induction therapy, patients with ALL may then receive intensification, consolidation, and maintenance courses of chemotherapy or allogeneic hematopoietic stem cell transplant (HSCT). Although CR is obtained in the majority of patients with ALL, maintaining a durable CR is challenging despite the numerous phases of therapy. Standard chemotherapy regimens have resulted in an average cure rate of only 35% (Bassan & Hoelzer, 2011). There are limited treatment options for patients with relapsed or refractory Philadelphia chromosome– negative (Ph–) ALL. Options may include enrollment into clinical trials or singleor multiagent chemotherapy regimens. Historically, these patients have had very poor outcomes, with reported CR rates of approximately 20% to 30% and a median overall survival (OS) of 3 to 6 months (National Comprehensive Cancer Network [NCCN], 2014; Topp et al., 2015). Given the poor outcomes seen with chemotherapy regimens in this setting, novel agents, such as blinatumomab (Blincyto), with alternative mechanisms of action are needed.
منابع مشابه
Blinatumomab, a Bi-Specific Anti-CD19/CD3 BiTE® Antibody for the Treatment of Acute Lymphoblastic Leukemia: Perspectives and Current Pediatric Applications
Leukemia is the most common childhood malignancy and acute lymphoblastic leukemia (ALL) represents the largest sub-type. Despite remarkable improvements over the last 40 years, standard therapy fails in 10-20% of newly diagnosed patients. Survival for children with relapsed ALL is poor, and the development and implementation of novel therapeutic strategies in pediatric ALL are critical to furth...
متن کاملComplete remission after single agent blinatumomab in a patient with pre-B acute lymphoid leukemia relapsed and refractory to three prior regimens: hyperCVAD, high dose cytarabine mitoxantrone and CLAG
BACKGROUND The current standard of care for relapsed and refractory acute lymphoblastic leukemia (ALL) is combination chemotherapy. CASE PRESENTATION We report a case of highly refractory ALL who was treated with blinatumomab. The ALL in this patient relapsed within a month after completion of hyperCVAD regimen and was refractory to high dose mitoxantrone/cytarabine and CLAG regimens. CONCL...
متن کاملBlinatumomab: a bispecific T cell engager (BiTE) antibody against CD19/CD3 for refractory acute lymphoid leukemia
Targeted therapy has been the forefront of cancer treatment. Cancer immunotherapy is the most recent focus. In addition, novel immunotherapeutics targeting B cell receptor signaling (e.g., ibrutinib), T cell receptor ( e.g., CART19), and NK cells (e.g., AFM13) are being developed. This review summarized the new development in blinatumomab (MT103/MEDI-538), a first-in-class bispecific T engager ...
متن کاملMetronomic Effect as A New Hypothesis in Maintenance Therapy of Acute Lymphoblastic Leukemia
متن کامل
Clinical use of blinatumomab for B-cell acute lymphoblastic leukemia in adults
Adults with relapsed or refractory B-cell acute lymphoblastic leukemia have a dismal prognosis with a short median overall survival that can be measured in months. Because most patients will have chemotherapy-resistant disease, allogeneic hematopoietic stem cell transplantation remains the only potentially curative treatment. Despite advances in current management, patients continue to have poo...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
دوره 7 شماره
صفحات -
تاریخ انتشار 2016